Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results
Stocks in this Quantisnow insightHealth Care
Historical context for AORT
Across the 15 sessions after earlier AORT headlines, the stock closed higher 9 times and lower 5 times, with a median move of 2.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | AORT | SPY |
|---|---|---|---|
| Jun 29, 2026 | Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis | -5.2% | +1.6% |
| Jun 11, 2026 | Artivion to Participate in the 2026 Truist Securities MedTech Conference | +0.6% | +1.7% |
| May 18, 2026 | Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch Systemand 1 other headline that session | +4.3% | -0.1% |
| May 8, 2026 | Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan | -28.3% | +0.8% |
| Apr 24, 2026 | Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results | +1.6% | +0.8% |
| Apr 10, 2026 | Artivion upgraded by Ladenburg Thalmann with a new price target | +3.1% | -0.1% |
Quantisnow market dataNYSE
AORT
Artivion Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
Get push alerts for AORT
Full AORT profile on Quantisnow Follow AORT and get a push notification the moment its next story breaks.